Five-year outcomes from neoadjuvant, adjuvant, and perioperative immunotherapy trials in resectable NSCLC clarify which patients benefit most.
|Videos|October 4, 2017
Dr. Villaflor Discusses Alectinib in ALK+ NSCLC
Author(s)Victoria Villaflor, MD
Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer.
Advertisement
Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non—small cell lung cancer (NSCLC).
The ALEX study of alectinib in patients with ALK-positive NSCLC demonstrated a significant benefit in progression-free survival versus standard-of-care crizotinib (Xalkori).
Advertisement
Related to this article
Sanja Dacic, MD, PhD, outlines advances that are reshaping molecular profiling in advanced non–small cell lung cancer and how to navigate these changes.
Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5